Background. We wished to determine the optimal duration of follow-up for patients with acute renal failure (ARF) treated with continuous renal replacement therapy (CRRT) and tested the hypothesis that a 6 month follow-up would be the minimum to catch most of the mortalities. In addition, we evaluated the association between mortality and the RIFLE classification in the same patients. Methods. We analysed the data of 8152 consecutive patients who had been admitted to the intensive care unit (ICU) of a Swedish university hospital between 1995 and 2001. Of that population, 207 patients were treated with CRRT, excluding 16 treated for non-renal indications.
Introduction
It is well known that compared with the general intensive care unit (ICU) population, patients with acute renal failure (ARF) have a higher hospital mortality [1] , ranging from 43% [2] to 88% [3] . Even the incidence of ARF varies: numbers from 1% to 25% have been reported [2, 4, 5] . One of the reasons for this variation might be the absence of an agreedupon biochemical definition of ARF and the lack of a uniform classification system. The already high mortality numbers become even higher for patients requiring renal support [6] .
Another concern in studying the epidemiology of ARF is the use of mortality: a large number of studies use ICU mortality [2, 7] or in-hospital mortality as endpoints [5, 8] . There has been an ongoing debate about when a stable survival rate is reached in ARF patients. Reported data show that this may take 30-60 days [9, 10] . The consensus from the second Acute Dialysis Quality Initiative (ADQI) conference was presented by Palevsky and co-workers [10] , who suggest using from 60 to 90 days of follow-up for the evaluation of all-cause mortality.
In the present study, we investigated a cohort of 223 ICU patients who were treated with continuous renal replacement therapy (CRRT) -16 had been treated for non-renal indications and were dropped from the study. Our primary aim was to determine the optimal duration of follow-up. We hypothesized that a 6 month follow-up might be needed. This was an arbitrary endpoint, but we wanted the time frame to be achievable and to include most of the occurring deaths. We assessed ICU, 30 day and hospital mortalities, as well as mortalities 2, 3 and 6 months after the start of treatment. We also looked at the causes of death. Our second aim was to evaluate the recently presented ARF classification system, the RIFLE criteria, as a tool for predicting the mortality of patients with ARF. These classification criteria have been presented by the ADQI group, but as yet they have not been tested in a clinical setting. The RIFLE criteria were developed to allow a more accurate and standardized stratification of groups of patients with ARF. However, in the document written by the ADQI workgroup for definitions of renal failure, it is pointed out that the criteria can be used for patients treated with or without dialysis (www.adqi.net).
Subjects and methods

Setting
The study was carried out in the general, multidisciplinary ICU at the Karolinska Hospital, a major university hospital in Stockholm. The ICU is the trauma referral centre of the greater Stockholm area (1.8 million inhabitants). The departments admitting there are surgery, urology, gynaecology, obstetrics, otorhinolaryngology and internal medicine. Thoracic and neurosurgical cases are admitted to the unit only if these conditions are part of a major trauma. The general ICU is an 8-13 bed unit treating around 1100 patients per year. About 50% of the patients stay >24 h and $40% are treated with mechanical ventilation.
Treatment modality
Three CRRT modalities [continuous veno-venous haemofiltration (CVVH), continuous veno-venous haemodialysis and continuous veno-venous haemodiafiltration (CVVHDF)] were in use in the ICU during the study period. Lactatebuffered solutions were preferred initially, but bicarbonatebuffered solutions have been used exclusively since 1997. Over the years, the trend has been away from CVVHDF towards CVVH, with replacement fluid amounts of 30-45 ml/kg/h. The filters in use are AN 69 M100 (Gambro, Sweden) with pre-dilution. Recently, however, CVVHDF using citrate as anticoagulant has become the most common treatment modality. The treatment is initiated by an intensive care physician and then carried out by ICU nurses.
Data collection
Between January 1995 and December 2001, a total of 8152 patients were admitted to the ICU. All admissions were documented and all but 16 CRRT patients were included in the study. The following information was recorded for each patient at entry and during treatment in a standardized manner by an intensive care nurse: demographic data, common pre-existing diseases, indication for ICU admission, main diagnosis, APACHE II score, major ICU interventions and laboratory results. The indication for dialysis was documented and specific data regarding the renal replacement therapy (RRT) were recorded daily. In reviewing the patients' files we looked at previous health status, organ function at the start of dialysis [11] and the relevant physiological and pharmacological data needed for the RIFLE classification. Moreover, we gathered information on the causes of death for the 29 patients who died within 31-180 days of admission. The study protocol was approved by the local ethics committee.
The RIFLE criteria
The RIFLE criteria were established during the second ADQI conference held in Vicenza in May 2002 and, subsequently, they were posted on the Internet for external review (www.adqi.net). They were published by the working group in a preliminary draft [12] and then were presented at the 8th International Conference on Continuous Renal Replacement Therapies in San Diego in 2003. The most recent document concerning RIFLE can be found on the Internet on the critical care forum [13] . The RIFLE classification system (Table 1) offers the tools to categorize and stratify a population of patients based on their renal function. According to glomerular filtration rate (GFR), serum creatinine (where change from the patient's individual baseline is measured) and urine output (UO), patients are classified into three severity categories: risk, injury and failure. Additionally, there are two outcome categories: loss and end-stage renal disease.
We assigned the patients in our cohort, i.e. those who had dialysis initiated, to RIFLE categories according to either their GFR/creatinine or their UO (whichever was more severe). The baseline creatinine of each patient was retrieved from the hospital laboratory database. If the baseline renal function was unknown, we used a reference creatinine as estimated from the MDRD (modification of diet in renal disease) equation [13] . The patient's RIFLE level (R, I or F) was then determined by calculating the relative change in functional criteria. The patients who did not fulfill the criteria were excluded from the study. These patients were treated with CRRT for non-renal indications.
A patient with pre-existing renal disease might pose a problem, since his or her baseline GFR and serum creatinine usually differ from the 'normal' patient's. Theoretically, this relative difference in the patient's creatinine could be quite small and, thus, result in placing the patient in a misleading RIFLE category. Kellum and co-workers propose that a separate criterion should be used for an ARF superimposed on chronic renal disease (www.adqi.net): an acute rise in creatinine (of !0.5 mg/dl or !44 mmol/l) to >4 mg/dl or >350 mmol/l identifies most patients with ARF when their baseline serum creatinine is abnormal. We used this criterion for the cases with 'acute-on-chronic' ARF. A number of the patients had end-stage renal disease, as defined here by the need for dialysis for >3 months (RIFLE-E).
A very small number of patients was enrolled in the study with persistent ARF; they had had RRT for between SCreat, serum creatinine.
Optimal follow-up time after CRRT 355 4 weeks and 3 months previously (RIFLE-L). Even though L and E are outcome categories in the RIFLE system, we chose to use those designations for the patients with preexisting renal disease requiring chronic dialysis. Otherwise, this subgroup would have been assigned to the F category, which we felt would have been misleading.
Outcome
We documented the cases discharged from the ICU still needing RRT. By using the national registration numbers assigned to Swedish residents since 1947 [14] , we could link our CRRT database with SRAU, the Swedish Register of Active Treatment of Uremia [15] . The registry was established in 1991 and includes each individual who, due to chronic renal disease had dialysis, kidney transplantation or both. Every change in treatment (haemodialysis, peritoneal dialysis, transplantation and discontinuation of treatment) is reported to the registry, to which all of the clinical departments in Sweden that offer some form of active uraemic care contribute data. By using this registry we could identify patients who left the ICU but needed chronic renal support. Those who left the ICU needing RRT for a finite period of time were documented in our own database, but not entered in SRAU. Most of the patients found after linkage with SRAU were dialysis-dependent prior to their ICU admissions. These patients, documented in our database, were found in SRAU both before and after their admission to the ICU. A smaller group of patients was found who had been entered in the registry only after their critical illness. The mortality rate was calculated at multiple points of time. ICU mortality was recorded and data on hospital mortality were extracted from the Karolinska Hospital's in-house database. This database is linked and cross-matched (via the national registration numbers) to the population registry run by Statistics, Sweden. Births and deaths are entered into the database on a daily basis. Therefore, we could compute all-cause mortality at 30, 60, 90, 120, 150 and 180 days (or for any given point of time further on).
Statistical methods
Crude survivals were estimated using the Kaplan-Meier estimator and are presented with 95% confidence intervals (CI). Cox regressions were performed for the univariate and multivariable analyses of mortality within 30 days of the start of dialysis, i.e. all subjects being censored at day 31. The variables included in these models are displayed in Table 2 . The final model is shown in Table 3 . The estimated impact of the RIFLE score did not change significantly after dropping selected variables. It should be noted that the multivariate analysis only looked at the patients scoring R, I or F; patients with pre-existing renal disease were excluded from the model. The multivariate analysis was performed to assess potential confounding by comparing the estimates derived from the univariate analysis and from the full multivariate analysis. The time-dependence of the prognostic value of the RIFLE score was assessed by considering it a pseudo-time-dependent covariate, allowing for differences in the influence of RIFLE during follow-up. These analyses showed no significant difference in influence in the period between days 0 and 15 compared with the period between days 16 and 30 -the estimates indicated a slightly higher impact of high RIFLE scores for the first period (data not shown). Similarly, we explored predictors for mortality beyond 30 days and found no significant predictors. We explored, in particular, the influence of the RIFLE score between days 31 and 60 and found no association between mortality and RIFLE in this interval. Results are presented as hazard ratios (HR) with 95% CI. It should be kept in mind, however, that these comparisons over time are hampered by a relatively low power and the lack of significant effects should not be interpreted as a demonstration of lack of effect. Wald tests were used to assess the overall statistical significance of each variable in the multivariate analysis. All analyses were performed using the Statistical Analysis System (SAS Õ ) package.
Results
During the 7 year study period, 223 adult, critically ill patients developed the need for acute RRT. Of them, 16 patients were treated with CRRT for non-renal indications and, therefore, were not included in the cohort for analysis.
Some 120 (58.0%) and 78 (37.7%) cases were admitted from surgical and medical departments, respectively, and nine (4.3%) patients came from other units; 153 patients (73.9%) had an APACHE II score of 18 or higher and 54 (26.1%) had a score of 28 or higher. Also illustrating the high illness severity in this cohort, 176 (85.0%) patients were treated with mechanical ventilation and inotropic support was used in 162 (78.3%) patients. Lengths of stay in the ICU averaged 14 days. CRRT was initiated within 24 h of ICU admission in 109 (52.7%) cases. Table 2 presents the clinical features of the cohort along with mortalities at 30 days as compared with mortalities between 31 days and 6 months. ICU mortality was 34.8% and hospital mortality was 50.2% compared with a mortality of 45.9% at 30 days. At 6 months, all-cause mortality reached 59.9%, but as early as after 2 months the mortality was 54.6%. A Kaplan-Meier plot illustrates this (Figure 1) .
Overall, 16 (7.7%) patients were dialysis-dependent prior to their admission to the ICU. These patients were categorized in the RIFLE-E group. Only three patients fitted the RIFLE-L criteria. The 19 cases (9.2%) of RIFLE-L and RIFLE-E that were treated with CRRT in the ICU had a mortality of 52.6% at 30 days (Table 2) . Patients categorized RIFLE-F had a higher mortality rate; these 121 (54.3%) patients had a HR of 3.4 (95% CI: 1.2-9.3) ( Table 3) and a mortality at 30 days of 57.9%.
The RIFLE-I group comprised 50 patients; their mortality rate was 22.0% at 30 days. The 17 patients in RIFLE-R had a 23.5% mortality ( Table 2 ). The RIFLE-F group also had a higher mortality rate for the period 31 days to 6 months as compared with RIFLE-R and -I (Table 2) . When the Kaplan-Meier plot is stratified according to RIFLE classifications, the differences between the survival curves of the 356 M. Bell et al. Wald's test of heterogeneity.
Optimal follow-up time after CRRT 357 three groups are obvious ( Figure 2 ). It is interesting to point out how the mortality of the RIFLE-L and -E patients, i.e. patients with pre-existing renal disease, actually surpasses that of the RIFLE-F group at 6 months of follow-up ( Figure 2 ). The causes of death are as follows. Of the 18 patients who died 31-60 days after inclusion in the cohort (i.e. initiation of dialysis in the ICU), 11 were categorized to have died from multiorgan failure, four cardiovascular deaths were recorded, two patients died from uraemia and one from cancer. For the 'late' mortalities, i.e. the 11 patients dying in the 61-180 days interval, five cardiovascular deaths were found, three patients died from cancer, two from multiorgan failure and one from uraemia.
Considering the survivors after 30 days, there were 112 patients. Seven of these, designated RIFLE-E, had had pre-admission RRT (and were included in the SRAU registry). When they were excluded, 105 patients were left. Out of this group, only five (4.8%) were permanently dialysis-dependent after their stays in the ICU (and were included in the SRAU registry). Four out of these five started chronic RRT as soon as they left the ICU and a fifth patient was monitored by nephrologists, but was not started on RRT until $3 years after the episode of critical illness.
Discussion
We have focused on two problems in the field of ARF epidemiology. First, optimal follow-up time remains to be determined. Second, the definition of ARF has been an issue for all researchers. The Novis et al. [4] review of 28 studies examining post-operative renal failure revealed 28 different definitions of ARF. In most cases, arbitrary biochemical cut-off points have been used, but some researchers have favoured the pragmatic approach, defining ARF as the need for RRT [16] . The patients needing RRT in the critical-care setting do have a particularly poor prognosis [17] [18] [19] . They were the focus of our investigation. Since clinicians initiate artificial renal support at different time-points, we felt that the use of the RIFLE criteria in the context of our study was warranted.
Our general results are in line with data from other studies. First, the mortality rate of severe ARF in the ICU is high, albeit lower in our cohort than in most comparable studies. Second, some patients are dialysisdependent prior to having a critical illness. Third, this group as a whole has a high level of illness severity, as illustrated by high APACHE II scores and the fact that $80% of the patients had associated respiratory and circulatory failure needing support. The protocol for managing ARF in our ICU is similar to that used in most Scandinavian centres and in Australia. Criticalcare physicians and critical-care nurses initiate and apply RRT and CRRT is almost always the method of choice.
Due to a number of practical reasons, in many previous studies the mortality measured has been ICU mortality or in-hospital mortality. This may not be sufficient, for this investigation shows a difference of 19.8% between ICU and 2 month mortalities. Also, taking into consideration the whereabouts of the patient at the time of death may reveal that local traditions influence mortality: the time for when patients are discharged from both the ICU and hospital varies between centres and countries. Comparing the ICU mortality to the mortality at 6 months, we see a difference of 25.1%. It could be argued that all-cause mortality at 6 months is too blunt an instrument; that it does not accurately measure the effects of ARF as such. This makes some sense. The higher mortality in our cohort at 6 months as compared with 30 days or 2 months could be a result of the general poor health of the population. Looking at the causes of death, we restricted our analysis to patients dying between 1 and 2 months and between 2 and 6 months. The numbers are small, but more cases of multiorgan failure were seen in the 31-60 day time-frame, implying that these mortalities were associated with the critical illness. Based on this patient cohort, in our opinion, a 2 month follow-up period is sufficient. First, the number of additional deaths between 61 and 180 days is small; second, the causes of death in this more distant time-frame do not seem to be associated strongly with the critical illness. Applying the RIFLE criteria revealed new insights. Firstly, the RIFLE classification is feasible and fairly straightforward. To our knowledge, this is the first group of ARF patients to whom it has been applied and it does add transparency and comparability to this type of cohort. Secondly, we found that the patients categorized as RIFLE-F had a far higher mortality than RIFLE-I and -R patients. Figure 2 illustrates the increased mortality for the F category both in the first 30 days after inclusion in the cohort and during the period from 31 days to 6 months. Interestingly, in our study elevated creatinine alone was not associated with increased mortality (Table 2 ), but, in contrast, oliguria seemed to be ( Table 2) . One conclusion that might be drawn is that the use of patients' baseline GFR/creatinine levels and the measured relative changes combined with UO sharpens the predictive ability of the system. We did not identify any confounding factors that biased the predictive ability of the RIFLE criteria -neither higher numbers of failing organs nor higher APACHE II scores (Table 3 ).
An important consideration that might, in part, explain the higher mortality of the F category is the fact that the category consists of different patient groups. The patients in this category could have a 3-fold increase in creatinine or anuria for 12 h or they could have a 5-fold creatinine increase or anuria for 24 h, but they still would be designated RIFLE-F. The RIFLE classification is designed to have a high sensitivity in the RIFLE-R group and a high specificity in the RIFLE-F group. Patients in the latter group do, indeed, suffer from renal failure, but the group as a whole is not as well defined. The fact that the mortality was much higher in RIFLE category F, compared with R and I, may support previous research showing that an early start of RRT can be beneficial [20] . The fact that RIFLE-I patients actually had a lower mortality than RIFLE-R patients might reflect only the small numbers of patients in the different categories.
It needs to be emphasized that this investigation was carried out in a clinical setting. This leads to heterogeneity in our cohort, making the RIFLE criteria useful. The data on the prognostic abilities of RIFLE must, however, be seen in light of the limits of this single-centre study. The higher mortality in the F category does not mean that RIFLE can be used as a predictor of treatment with impunity. Moreover, we cannot extrapolate these data to all cases of ARF -this study focused on CRRT. It would have been interesting to study all patients with ARF, but we did not have that opportunity. We are currently using the RIFLE criteria in a new project where all patients with ARF are included, not just those requiring CRRT. Also, testing the predictive abilities of the RIFLE criteria against other existing ARFspecific models calls for a separate study.
Lastly, only five patients out of 118 (4.2%) were left with a dialysis-dependent renal insufficiency after their critical illness. It has to be kept in mind that one of these patients started RRT almost 3 years after his episode of ARF. After the study ended in December of 2001, some patients have only been followed for 18 months and it is possible that more patients may eventually require RRT.
In conclusion, the mortality of patients treated with CRRT is very high. While ICU and in-hospital mortalities reflect local traditions of patient discharge, a 2 month follow-up period may be optimal for determining mortality rates in other more or less similar cohorts. The recently developed RIFLE classification system was found to be a valuable tool. It adds transparency to this study of ARF and it may be even more useful in studies where conservative treatment and RRT are compared.
